Bivalent influenza modRNA vaccine(BioNTech/Pfizer)

N/A

Report date: 2023/11/06 20:04:57

Base Information

Drug NameBivalent influenza modRNA vaccine(BioNTech/Pfizer)

Drug Alias NamemIRV(BioNTech/Pfizer)

ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccineVaccines > Vaccine type > Multivalent vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsInfluenza, Human

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc

Inactive CompaniesN/A

Active IndicationsInfluenza, Human

Inactive IndicationsN/A

Other Information

ATC CodeN/A